


# Strut thickness and type of metal alloy of bare metal stents and frequency of in-stent-restenosis: Data from the Swedish Angiography and Angioplasty Registry (SCAAR).

Torsten Schwalm<sup>1</sup>, Per Tornvall<sup>2</sup>, Stefan James<sup>3</sup>, Bo Lagerqvist<sup>3</sup>, Maria Homburg<sup>1</sup>, Anja Heinen<sup>1</sup>, Jörg Carlsson<sup>1</sup>,  
on behalf of the SCAAR study group


<sup>1</sup>Dept. of Cardiology, Länssjukhuset i Kalmar; <sup>2</sup>Dept. of Cardiology, Karolinska Sjukhuset, Stockholm; <sup>3</sup>Uppsala Clinical Research Center and Akademiska sjukhuset, Uppsala; all Sweden

**Background:** The likelihood of in-stent-restenosis is influenced by patient characteristics, clinical circumstances, lesion characteristics and type of stent used. Among the stent factors that influence restenosis rates strut thickness is believed to be a determinant of in-stent-restenosis where ISAR-STEREO and ISAR-STEREO-2 showed that thinner struts were associated with lower restenosis rates. These studies used two stents with extreme strut thicknesses, which were 50  $\mu\text{m}$  and 140  $\mu\text{m}$ . We used the SCAAR database to investigate the question whether “thinner is better” applies to currently used BMS that only have a range of strut thickness between about 60  $\mu\text{m}$  and 100  $\mu\text{m}$ . Furthermore, we analyzed the influence of type of metal alloy on restenosis rates. SCAAR has been described in detail before [1, 2].


**Methods and results:** Restenosis rates were investigated in 111 889 stents. The patients were included between May 1, 2005 and April 6, 2010. The follow-up after implantation ended October 6, 2010 with a minimum follow-up of 6 months and a maximum follow-up of 5 years and 5 months (mean follow-up 1080 days  $\pm$  523). The data were analyzed with regard to BMS, DES, different BMS types, stent strut thickness and metal alloy composition. The analysis was adjusted for differences in baseline characteristics known to influence restenosis rate. 75 448 stents were BMS with strut thickness between 65  $\mu\text{m}$  and 100  $\mu\text{m}$ . The figure 2 shows the adjusted frequency of restenosis depending on strut thickness. The relative risk was 0.995 for thicker struts (95% confidence interval 0.990-0.999),  $p=0.017$ .




**Figure 1: Cumulative crude risk of in-stent restenosis depending on strut thickness**



**Figure 2: Cumulative adjusted risk of in-stent restenosis depending on strut thickness (RR 0.995 for thicker struts; 95% CI 0.995-0.999;  $p=0.017$ )**



**Figure 3: Cumulative crude risk of in-stent restenosis depending on metal alloy**



**Figure 4: Cumulative adjusted risk of in-stent restenosis depending on metal alloy (RR 1.009; 95% CI 0.926-1.100;  $p=0.9$ )**

## Limitations

As always with retrospective evaluations of registry data, there are inherent limitations mainly regarding unknown confounders. Despite appropriate statistical adjustments, there might remain important differences in baseline characteristics and/or selection criteria that are unrecorded.

**Conclusions:** Thus, the old dogma that thinner stent struts are associated with lower restenosis rates may no longer be true with modern BMS. Metal alloy had no influence on restenosis rates.

## References

- James SK, Stenstrand U, Lindbäck J, Carlsson J, et al. Long-term safety and efficacy of drug-eluting versus bare metal stents in Sweden. *N Engl J Med* 2009;360:1933-45
- Lagerqvist B, Carlsson J, Fröbert O, et al. Stent thrombosis in Sweden. A report from the Swedish Coronary Angiography and Angioplasty Registry. *Circ Cardiovasc Interv* 2009;2:401-8

**Disclosures** no conflict of interest.